Shots:

• Pfizer to acquire Array Biopharma in all-stock transaction for $48/share making the total deal value ~11. Table4B- with its expected completion in H2’19
• The focus of the acquisition is to bolster Pfizer’s oncology portfolio with the addition of Array’s combined therapy of Braftovi (encorafenib) and Mektovi (binimetinib) indicated for the treatment of BRAF^V600E or BRAF^V600K mutant unresectable or metastatic melanoma
• Braftovi and Mektovi are BRAF/MEK inhibitors- being evaluated in P-III BEACON study as a triple combination therapy (braftovi + mektovi + cetuximab) in patients with BRAF-mutant mCRC with its expected regulatory submission in the US in H2’19

Ref: Pfizer | Image: Leaderonomics